a public good project by the
Synthesis
Company
of California

© 2026

Anna Polli | doi.page

0 works0 citations0 h-index

Anna Polli

Pfizer (United States)(US)Pfizer (Italy)(IT)The Fertilizer Institute(US)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, Colorectal Cancer Treatments and Studies, Estrogen and related hormone effects

Most-Cited Works

→ Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer(2013)3,388 cited
→ First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer(2020)1,029 cited
→ A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea(1994)693 cited
→ Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases(2015)604 cited
→ Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial(2000)525 cited
→ Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial(2000)318 cited

→ Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer(2005)294 cited

→ Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study(2024)275 cited

→ Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study(2022)213 cited

→ Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.(2011)174 cited